Author Correction: Establishing a universal IVRP method for quadrivalent HPV vaccines to replace in vivo potency tests

Author Correction: Establishing a universal IVRP method for quadrivalent HPV vaccines to replace in vivo potency tests

Saved in:

Bibliographic Details
Main Authors:	Jinpan Hu, Zijing Jia, Meng Wang, Lingling Nie, Wangjun Fu, Qingfeng Zhang, Haiyang Qin, Jianhui Nie, Xiaoyu Xu, Lingjie Xu, Fengze Wang, Yingping Chen, Bo Xing, Tao Li, Danfeng Li, Shaowei Li, Ningshao Xia, Xiangxi Wang, Weijin Huang
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-05-01
Series:	npj Vaccines
Online Access:	https://doi.org/10.1038/s41541-025-01142-9
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Establishing a universal IVRP method for quadrivalent HPV vaccines to replace in vivo potency tests
by: Jinpan Hu, et al.
Published: (2025-03-01)

Distribution of HPV types among women with HPV-related diseases and exploration of lineages and variants of HPV 52 and 58 among HPV-infected patients in China: A systematic literature review
by: Meng Wang, et al.
Published: (2024-12-01)

The Current Status in Terms of Vaccination for Individuals Infected with Human Immunodeficiency Virus
by: Nan Xu, et al.
Published: (2025-01-01)

Four-Color Pseudovirus-Based Neutralization Assay: A Rapid Method for Evaluating Neutralizing Antibodies Against Quadrivalent Hand, Foot, and Mouth Disease Vaccine
by: Fan Gao, et al.
Published: (2025-03-01)

Progress Update on STING Agonists as Vaccine Adjuvants
by: Yanru Shen, et al.
Published: (2025-03-01)

HIV-1 pseudoviruses constructed in China regulatory laboratory
by: Jianhui Nie, et al.
Published: (2020-01-01)

Safety and immunogenicity of full-dose quadrivalent influenza vaccine in children 6–35 months of age in China: A randomized, double-blind, clinical trial
by: Shilei Wang, et al.
Published: (2024-12-01)

GARDASIL. QUADRIVALENT RECOMBINANT VACCINE AGAINST HPV (6, 11, 16, 18 TYPES)
by: article editorial
Published: (2007-04-01)

Quadrivalent HPV (4vHPV) vaccine immunogenicity and safety in women using immunosuppressive drugs due to solid organ transplant
by: Karina Takesaki Miyaji, et al.
Published: (2024-11-01)

Neutralization potency of the 2023-24 seasonal influenza vaccine against circulating influenza H3N2 strains
by: Xiande Huang, et al.
Published: (2024-12-01)

An overview of the meningococcal disease and impact of the quadrivalent meningococcal conjugate vaccine
by: Asmaa Alrobai, et al.
Published: (2021-12-01)

Cost-effectiveness of quadrivalent human papillomavirus vaccination in adolescent girls
by: A. V. Rudakova, et al.
Published: (2016-11-01)

Assessment of Reactogenicity and Immunogenicity of the Quadrivalent Live Attenuated Influenza Vaccine
by: D. A. Lioznov, et al.
Published: (2018-06-01)

The averted costs due to influenza vaccination with trivalent and quadrivalent vaccines
by: S. M. Kharit, et al.
Published: (2017-06-01)

Research Progress on Hepatitis E Virus Culture
by: Jie Zhang, et al.
Published: (2025-05-01)

Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
by: Eliel Nham, et al.
Published: (2023-12-01)

Evaluation of determinants of the serological response to the quadrivalent split‐inactivated influenza vaccine
by: Shaohuan Wu, et al.
Published: (2022-05-01)

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
by: Jianhui Nie, et al.
Published: (2020-01-01)

An mpox quadrivalent mRNA vaccine elicits sustained and protective immunity in mice against lethal vaccinia virus challenge
by: Entao Li, et al.
Published: (2025-12-01)

Optimization for the production of a dengue live-attenuated Quadrivalent vaccine in Vero cells grown on microcarriers
by: Shannon Haughney, et al.
Published: (2025-06-01)

Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Adolescent Girls in Russian Federation
by: Alla V. Rudakova, et al.
Published: (2018-01-01)

Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine for older adults in South Korea
by: Youngji Song, et al.
Published: (2024-12-01)

On Approval of the Plan for a Phased Transition to the Use of Quadrivalent Vaccines for the Prevention of Influenza
by: article Editorial
Published: (2019-03-01)

Development of a neutralization assay and bioluminescent imaging mouse model for Dehong virus (DEHV) using a pseudovirus system
by: Xuelian Wu, et al.
Published: (2025-05-01)

Aggregation potency and proinflammatory effects of SARS-CoV-2 proteins
by: Monica Costa, et al.
Published: (2025-08-01)

Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years with or without previous influenza vaccination histories
by: Feng Wen, et al.
Published: (2025-12-01)

Multiple infections with Omicron variants increase breadth and potency of Omicron-specific neutralizing antibodies
by: Lei You, et al.
Published: (2025-05-01)

Discovery of a novel PLK1 inhibitor with high inhibitory potency using a combined virtual screening strategy
by: Zhen Xu, et al.
Published: (2025-12-01)

Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1
by: Shuo Liu, et al.
Published: (2023-12-01)

Comparison on virulence and immunogenicity of two recombinant vaccinia vaccines, Tian Tan and Guang9 strains, expressing the HIV-1 envelope gene.
by: Rong Zhu, et al.
Published: (2012-01-01)

Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities
by: Jianhui Nie, et al.
Published: (2019-01-01)

Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine
by: Neerja Bhatla, et al.
Published: (2023-12-01)

INFLUENZA VACCINATION OF CHILDREN OF PRESCHOOL AGE IN THE RUSSIAN FEDERATION: COST-EFFECTIVENESS OF QUADRIVALENT VACCINE
by: A. V. Rudakova, et al.
Published: (2019-03-01)

FIRST APPLICATION EXPERIENCE OF THE QUADRIVALENT VACCINE FOR PREVENTION OF THE PAPILLOMA VIRAL INFECTION AND CERVICAL CANCER
by: M.G. Galitskaya, et al.
Published: (2008-07-01)

A new quadrivalent meningococcal tetanus toxoid conjugate vaccine: Menquadfi® (MENACWY-TT)
by: Ener Cagri Dinleyici, et al.
Published: (2025-12-01)

Maintaining the value of influenza vaccination – the shift from quadrivalent to trivalent vaccines: an expert review
by: David Fisman, et al.
Published: (2025-12-01)

Post-marketing surveillance for the safety of the quadrivalent human papillomavirus vaccine: a retrospective real-world study in China
by: Ruogu Meng, et al.
Published: (2025-12-01)

Novel Trispecific Neutralizing Antibodies With Enhanced Potency and Breadth Against Pan‐Sarbecoviruses
by: Rui Qiao, et al.
Published: (2025-05-01)

Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector
by: Ziteng Liang, et al.
Published: (2023-12-01)

Risk of developing juvenile idiopathic arthritis after quadrivalent HPV vaccination: a retrospective cohort study using the TriNetX U.S. Network
by: Wen-Yu Wu, et al.
Published: (2025-08-01)